Jazz Pharmaceuticals Completes Acquisition of GW Pharma and Adds Epidiolex to Its Portfolio
In 2020, Epidiolex - which represents Jazz's third high-growth commercial franchise - surpassed 500 million dollars in annual net sales
Published on 06/13/2026
Curation and editing by Sechat Content, with information from Benzinga (Jelena Martinovic)
Bio-pharmaceutical company Jazz Pharmaceuticals has completed the acquisition of cannabis pharmaceutical company GW Pharmaceuticals. The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders.
>>> Follow Sechat on INSTAGRAM
The Jazz-GW Pharma Deal
In summary, under the terms of the agreement, the Ireland-based company agreed to acquire the FDA-approved cannabidiol prescription drug producer, Epidiolex, for 7.2 billion dollars or 6.7 billion dollars net of GW Pharma's cash.
GW ADS holders, with each representing 12 ordinary shares, would receive 220 dollars for each GW ADS, including 200 dollars in cash and 20 dollars in Jazz ordinary shares. Additionally, each GW ADS is equal to 0.12036 Jazz ordinary share.
Chris Tovey, who has served as COO of GW since 2012, has chosen to join Jazz's executive management as Executive Vice President, Chief Operating Officer, and Managing Director for Europe and International Countries.
What This Means for Jazz
The acquisition brings Epidiolex - an FDA-approved oral cannabidiol solution for patients one year and older to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex - to Jazz's portfolio.
In 2020, Epidiolex, which represents Jazz's third high-growth commercial franchise, surpassed 500 million dollars in annual net sales.
>>> Join Sechat's TELEGRAM group and be the first to receive news
"The addition of GW further diversifies our commercial portfolio and innovative pipeline with therapies that are complementary to our existing businesses," said Jazz Pharmaceuticals' President and CEO, Bruce Cozadd, on Wednesday (4).
What Comes Next
As a result of the acquisition, the combined company is expected to generate double-digit revenue growth in the next semester. "We look forward to building an even stronger company together. We are excited about the greater impact we will continue to make for patients, customers, and shareholders," Cozadd added.
>>> Join Sechat's WHATSAPP group and be the first to receive news
